Funded Startups in Doylestown
Ten funded-company entries are listed for Doylestown, spanning rounds dated 2020-06-04 (Powerlytics) through 2025-10-28 (Eliksa Therapeutics).
Ten funded-company entries are listed for Doylestown, spanning rounds dated 2020-06-04 (Powerlytics) through 2025-10-28 (Eliksa Therapeutics). The disclosed funding amounts show a clear outlier: Evrys Bio’s $34M grant on 2021-07-13 is the only disclosed round above $10M; all other disclosed amounts are $6M or less, with several smaller checks such as Korio’s $6M (2024-09-10), Kannalife’s $2M (2024-06-25), and A Woman’s Place’s $100K (2023-08-14).
Sector-wise, biotechnology is the dominant cluster: 4 of 10 companies (Eliksa Therapeutics, Kannalife, Mid-Atlantic BioTherapeutics, and ImCare Biotech, plus Evrys Bio) are labeled under biotechnology-related categories, and another 1 of 10 is Information Technology (Ory Corp) while Design appears once (Wethrivv). Staging is uneven: 5 of 10 entries are “Series Unknown,” and 1 of 10 is explicitly “undisclosed” (Eliksa Therapeutics, 2025-10-28). Most activity concentrates in 2024: 5 entries close between 2024-04-02 and 2024-09-10, including three biotechnology rounds (Kannalife, Mid-Atlantic BioTherapeutics, and Ory Corp).
Most recent rounds
10 shownRelated listings
Frequently asked
Which disclosed round is largest in Doylestown among the shown entries, and how does it compare to the rest?
Evrys Bio’s $34M on 2021-07-13 is the largest disclosed amount in this list and sits far above the next tier, where Korio’s $6M (2024-09-10) and Kannalife’s $2M (2024-06-25) anchor the lower disclosed range.
Is there a time cluster in these Doylestown rounds, or are they spread evenly across years?
The 2024 window is the densest cluster: five entries are dated from 2024-04-02 (Ory Corp) through 2024-09-10 (Korio). Outside that, activity is thinner, with single entries at 2025-10-28 (Eliksa Therapeutics) and 2020-06-04 (Powerlytics).
How dominant is biotechnology in this Doylestown set, and which other sectors appear?
Biotechnology-related labels account for 4 of 10 clear biotechnology entries (Kannalife, Mid-Atlantic BioTherapeutics, ImCare Biotech, and Evrys Bio), with Eliksa Therapeutics also labeled Biotechnology. Other singletons include Information Technology (Ory Corp, 2024-04-02) and Data and Analytics (Powerlytics, 2020-06-04).
What stage information patterns show up most often (and what’s missing)?
“Series Unknown” appears in 5 of 10 entries, including Kannalife (2024-06-25, $2M) and Mid-Atlantic BioTherapeutics (2024-06-19, $5M). One entry is explicitly “undisclosed” (Eliksa Therapeutics, 2025-10-28), while named stages include Seed (ImCare Biotech on 2023-07-14, $150K; Wethrivv on 2023-02-02, $650K) and Series A (Kor io on 2024-09-10, $6M).
Are there outliers besides the largest disclosed amount, such as unusually small checks or a single low- or high-range pocket?
The smallest disclosed amount is A Woman’s Place at $100K on 2023-08-14, which is far below the next-small disclosed figures like ImCare Biotech’s $150K (2023-07-14) and Wethrivv’s $650K (2023-02-02). In the high range, Evrys Bio’s $34M (2021-07-13) is the only disclosed round above $10M, making it the standout funding outlier.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.